FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 235 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in... March 11, 2024 FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC November 27, 2025 EMA Recommends Granting a Marketing Authorisation for Sugemalimab June 21, 2024 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Load more HOT NEWS Foster Teen With A Passion For Painting Is Patiently Waiting For... FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... ESMO awards its first fellowship to support digital and computational pathology Active Surveillance for Low-Risk Prostate Cancer Continues to Rise
